Cortex Pharmaceuticals' CEO Participates in the Life Science Mission to Israel; Stoll Receives the Albert Einstein Award for Outstanding Achievement in Life Sciences.IRVINE, Calif. -- Roger Stoll, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cortex Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : COR), was one of 50 leaders from the U.S. in the health sciences field invited to participate in the Life Science Mission to Israel during the last week of June. The mission was sponsored by The New Jerusalem Foundation, the Jerusalem Development Authority and Global Capital Associates. This group of U.S. healthcare leaders in academia, industry and capital markets met with numerous venture groups, industry, and academic, and government leaders from Israel to explore potential opportunities for relationships with their U.S. counterparts. Dr. Stoll was one of nine participants to receive the Albert Einstein Award The Albert Einstein Award (sometimes called the Albert Einstein Medal because it is accompanied with a gold medal) is an award in theoretical physics, that was established to recognize high achievement in the natural sciences. for Outstanding Achievements in the Life Sciences at a ceremony on June 29th in Jerusalem. The Albert Einstein Award for Outstanding Achievement in the Life Sciences salutes path-breaking leaders whose vision and commitment have contributed to the critical advancement of vital life-saving and life-enhancing technology to the benefit of mankind. It also has been previously awarded to leaders in the IT field. Over his 30-year career, Dr. Stoll has distinguished himself as a leader in general management, research and development, manufacturing, business development and strategic planning in the pharmaceutical and medical products industry. About Cortex Pharmaceuticals Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , Alzheimer's disease and anxiety disorders Anxiety disorders A group of distinct psychiatric disorders characterized by marked emotional distress and social impairment, including generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, and posttraumatic stress disorder. . (http://www.cortexpharm.com/) Forward-Looking Statement forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. Note - This press release contains forward-looking statements concerning the Company's research and development activities. The success of such activities depends on a number of factors, including the risks that the Company's proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical test and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion